FDA Meetings on Vaccines

Published on April 27, 2025April 27, 2025 by Shema Satya

During the Plandemic,
Shema tracked some of the FDA meetings on the
vaccines and related biological products

U.S. Food and Drug Administration
Meetings that are shared on their YouTube channel

FDA Meetings on Vaccines and Related Biological Products Advisory Committee

Join the U.S. Food and Drug Administration for an upcoming meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss considerations for future COVID-19 vaccine booster doses and the process for selecting specific strains of the SARS-CoV-2 virus for COVID-19 vaccines to address current and emerging variants.

Join the U.S. Food and Drug Administration for an upcoming meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss newly available data for the currently available COVID-19 vaccines.

The committee will meet to discuss a request to amend Pfizer-BioNTech’s Emergency Use Authorization (EUA) for administration of their COVID-19 mRNA vaccine to children 5 through 11 years of age.

On Oct. 15, the VRBPAC will discuss amending the emergency use authorization of Johnson and Johnson’s Janssen COVID-19 Vaccine for the administration of a booster dose, in individuals 18 years of age and older.

Additionally, on Oct. 15, the committee will hear a presentation from the National Institute of Health’s National Institute of Allergy and Infectious Diseases on the heterologous use of booster doses following the primary series of the three currently authorized or approved COVID-19 vaccines.

On Oct. 14, the committee will discuss an amendment to the emergency use authorization of the Moderna COVID-19 Vaccine for the administration of a booster dose, in individuals 18 years of age and older.

Join us for a Vaccines and Related Biological Products Advisory Committee meeting to discuss Pfizer-BioNTech’s supplemental Biologics License Application for administration of a third dose, or “booster” dose, of the COVID-19 vaccine, Comirnaty, in individuals 16 years of age and older.

The U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) will convene a virtual meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on June 10, 2021.

During the meeting the agency will provide a status update on our approach to emergency use authorization (EUA) for COVID-19 vaccines intended for use in individuals 12 through 17 years of age. The committee will also discuss the data needed to support an EUA and a biologics license application (BLA) for a COVID-19 vaccine intended for use in children less than 12 years of age. The committee will not discuss any specific products.

166th Meeting of the Vaccines and Related Biological Products Advisory Committee – June 10, 2021

The Committee will meet in open session to discuss, in general, data needed to support authorization and/or licensure of COVID-19 vaccines for use in pediatric populations.

00:00 – Opening Remarks and Administrative Announcements
22:29 – FDA Introduction, Ramachandra Naik, Ph.D
40:50 – CDC: Epidemiology of COVID-19 in the Pediatric Populations, LCDR. Hannah Kirking, M.D
01:15:32 – CDC: Operational Aspects, Shannon Stokley, DrPH
01:29:54 – Post-Authorization Surveillance Activities, Steven Anderson, Ph.D.
01:41:02 – COVID-19 Vaccine Safety Updates, CAPT. Tom Shimabukuro, M.D. M.PH. M.B.A.
02:15:38 – FDA Presentation – Considerations on Data to Support Licensure and Emergency Use Authorization of COVID-19 Vaccines for Use in Pediatric Populations, Doran Fink, M.D., Ph.D.
03:07:29 – Industry Perspective: Considerations for COVID-19 Vaccine Pediatric Trials, Phyllis Arthur, M.B.A.
03:17:32 – Open Public Hearing (OPH)
05:57:00 – Committee Discussion

The Committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2021 – 2022 influenza season.

The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Feb. 26 to discuss the request for emergency use authorization (EUA) of a COVID-19 vaccine from Janssen Biotech Inc.

The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) of a COVID-19 vaccine from Moderna, Inc.

A public meeting of the Vaccines and Related Biological Products Advisory Committee will be held on Oct. 22, 2020, to discuss the general matter of the development, authorization, and/or licensure of vaccines indicated to prevent COVID-19

The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 10 to discuss the request for emergency use authorization (EUA) of a COVID-19 vaccine from Pfizer, Inc. in partnership with BioNTech Manufacturing GmbH.

Heart Plan Vision

Living A Heart Centered Life

FDA Meetings on Vaccines